Long-acting injectable risperidone in treatment resistant borderline personality disorder. A small series report;Risperidona intramuscular de acción prolongada en el trastorno límite de la personalidad resistente al tratamiento. Un estudio piloto

Actas Espanolas de Psiquiatria

Volumn 36, Issue 2, 2008, Pages 70-74

  Díaz Marsá, Marina ^a   Galian, M ^a   Montes, A ^a   Fernandez R ^a   Arza, R ^a   Lopez Ibor J J ^a   Carrasco, J L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Borderline personality disorders; Risperidone

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; BORDERLINE STATE; DELAYED RELEASE FORMULATION; DRUG RESISTANCE; FEMALE; HOSPITALIZATION; HUMAN; MALE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; RISPERIDONE; SEVERITY OF ILLNESS INDEX;

EID: 42549135091     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary trial of fluoxetina, olanzapine, and the olanzapine-fluoxetine combination in women with borderlinepersonality disorder. J Clin Psychiatry 2004;65:903-7.
2. Bogenschutz MP, George Numberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004;65:104-9.
3. Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Álvarez E, et al. Bouble-blind, placebo-controlled study of dialectical behaviour therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005;162:1221-4.
4. Rocca P, Manchairo I, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002;63:241-4.
5. Pascual JC, Oller S, Soler J, Barrachina J, Álvarez E, Pérez V. Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. J Clin Psychiatry 2004; 65:1281-2.
6. Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005;162:621-4.
7. Nickel M, Nickel C, Kaplan P, Lahmann C, Muhlbacher M, Tritt K, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind placebo-controlled study. Biol Psychiatry 2005;1;57:495-9.
8. Mattes JA. Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2005;25:575-9.
9. Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005;19:287-91.
10. Paris J, Zweig-Frank H, Guzder H. The role of psychological factors in recovery from borderline personality disorder. Compr Psychiatry 1993;34:410-3.
11. First MB, Gibbon M, Spitzer RL, Williams JBW, Smith B, L. SCID-II. Entrevista clínica estructurada para el diagnóstico de los trastornos de la personalidad del eje II del DSM-IV. Barcelona: Masson, 1999.
12. Zanarini MC. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord 2003;17:233-42.
13. Guy W. 048 HAMA Hamilton Anxiety Scale. ECDEU Assessment Manual, U.S. Department of Health and Human Services, Public Health Service-Alcohol, Drug Abuse, and Mental Health Administration. Rev 1976, p. 194-8.
14. Hamilton M. A rating scale for depression. J Neurol, Neurosurg Psychiatry 1960;23:56-62.
15. Thompson PA, Buckley PF. The Brief Psychiatric Rating Scale: effect of scaling system on clinical response assessment. Meltzer HY J Clin Psychopharmacol 1994;14:344-6.
16. Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry 143:35-9.
17. Nickel M, Muhlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, et al. Aripiprazole in the treatmet of patients with borderline personality disorder: a double blind, placebo-controlled study. Am J Psychiatry 2006;163:833-8.
18. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine for the treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005;66:1298-303.
19. Pascual JC, Madre M, Soler J, Barrachina J, Campins MJ, Álvarez E, et al. Injectable atypicals antipsychotics for agitation in borderline personality disorder. Pharmacopsychiatry 2006;39:117-8.
20. Taylor DM, Young C, Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 2006;9:685-94.
21. Ferdekens M, Van Hove J, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Res 2004;70:91-100.
22. Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK. Usefulness of long-acting injectable risperidone during 12 month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1219-23.